ArticleChina CDC weekly2026
Safety of PCV13 with Different Carrier Proteins (CRM197, TT, and TT/DT) - Jiangsu Province, China, 2022-2024.
Article in China CDC weekly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aimed to evaluate the safety of three kinds of 13-valent pneumococcal conjugate vaccines (PCV13) with different carrier proteins - cross-reactive material 197 (CRM197), tetanus toxoid (TT), and a novel tetanus toxoid/diphtheria toxoid (TT/DT) dual-carrier - by monitoring adverse events following immunization (AEFI) in Jiangsu Province, China. Methods: The Chinese National Adverse Events Following Immunization Information System and Jiangsu Province Vaccination Integrated Service Management Information System were used. Reporting rates (RR) per 100,000 doses were calculated and stratified. Chi-square tests with Bonferroni correction and disproportionality analyses were performed. Results: A total of 1,734,810 PCV13 doses were administered, with 5,195 AEFI reports (RR=299.46 per 100,000 doses). RR was highest for TT/DT-carrier (399.84 per 100,000 doses) versus CRM197-carrier (286.69 per 100,000 doses) and TT-carrier (286.01 per 100,000 doses). Common adverse reactions accounted for 98.23% (5,103/5,195) of all AEFIs, with fever, local redness, and induration being the most common. Disproportionality analysis revealed positive signals for general reactions. Conclusion: All three PCV13 carrier protein types demonstrated acceptable safety profiles in Jiangsu Province from 2022 to 2024. Despite a higher RR for TT/DT-carrier PCV13 than for the other two PCV13 carrier protein types, most AEFIs were mild and common reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.